share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  04/19 16:21

Moomoo AI 已提取核心信息

On April 17, 2024, 180 Life Sciences Corp. announced significant changes to its financial oversight and legal proceedings. The company, with the approval of its Audit Committee, has dismissed Marcum LLP as its independent registered public accounting firm and has engaged M&K CPAs, PLLC for the fiscal year ending December 31, 2024. The previous audit reports by Marcum for the years ending December 31, 2023, and 2022 did not contain any adverse opinions, except for an uncertainty regarding the company's ability to continue as a going concern. In legal matters, 180 Life Sciences reported progress in its ongoing litigation with AmTrust International Underwriters DAC and Freedom Specialty Insurance Company. The court granted partial summary judgment in favor of 180 Life Sciences, affirming the company's insured status and...Show More
On April 17, 2024, 180 Life Sciences Corp. announced significant changes to its financial oversight and legal proceedings. The company, with the approval of its Audit Committee, has dismissed Marcum LLP as its independent registered public accounting firm and has engaged M&K CPAs, PLLC for the fiscal year ending December 31, 2024. The previous audit reports by Marcum for the years ending December 31, 2023, and 2022 did not contain any adverse opinions, except for an uncertainty regarding the company's ability to continue as a going concern. In legal matters, 180 Life Sciences reported progress in its ongoing litigation with AmTrust International Underwriters DAC and Freedom Specialty Insurance Company. The court granted partial summary judgment in favor of 180 Life Sciences, affirming the company's insured status and coverage for certain SEC subpoena-related expenses. However, issues regarding the Change in Control exclusion remain unresolved and will be determined at trial. The company has already received $2.27 million from AmTrust, of which $1.5 million was retained after attorney's fees. The final matters of the litigation are to be vigorously pursued by 180 Life Sciences.
2024年4月17日,180生命科学公司宣布对其财务监督和法律程序进行重大调整。经审计委员会批准,该公司已解除Marcum LLP作为其独立注册会计师事务所的资格,并已在截至2024年12月31日的财政年度聘请了M&K CPA, PLLC。Marcum先前对截至2023年12月31日和2022年12月31日的年度的审计报告不包含任何负面意见,但公司继续作为持续经营企业的能力存在不确定性外。在法律事务方面,180 Life Sciences报告了与AmTrust国际承保人DAC和自由专业保险公司正在进行的诉讼的进展。法院作出了有利于180 Life Sciences的部分即决判决,确认了该公司的...展开全部
2024年4月17日,180生命科学公司宣布对其财务监督和法律程序进行重大调整。经审计委员会批准,该公司已解除Marcum LLP作为其独立注册会计师事务所的资格,并已在截至2024年12月31日的财政年度聘请了M&K CPA, PLLC。Marcum先前对截至2023年12月31日和2022年12月31日的年度的审计报告不包含任何负面意见,但公司继续作为持续经营企业的能力存在不确定性外。在法律事务方面,180 Life Sciences报告了与AmTrust国际承保人DAC和自由专业保险公司正在进行的诉讼的进展。法院作出了有利于180 Life Sciences的部分即决判决,确认了该公司的保险状况以及某些与美国证券交易委员会传票相关的费用的承保范围。但是,有关控制权变更排除的问题仍未解决,将在审判中确定。该公司已经从AmTrust获得了227万美元,其中150万美元是在扣除律师费后留存的。180 Life Sciences 将积极处理诉讼的最后事项。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息